Loading market dashboard
Evogene Ltd.
EVGNHealthcareNASDAQIL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd.
EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q1 2026. All amounts are in Canadian dollars and are presented in thousands of dollars unless otherwise stated and have been prepared in accordance with IFRS. Financial Highlights The following table presents EverGen's Consolidated Financial and Operating Summary: Three months ended Mar 31, 2026 Mar 31, 2025 $ Cha.
Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.
Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in the 24th Schrödinger European User Group Meeting, taking place May 19–21, 2026, in Munich, Germany.
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the first quarter 2026, on Wednesday , May 20 , 2026.
EverGen Infrastructure Corp. (EVGN:CA) Q4 2025 Earnings Call Transcript
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQB: EVGIF), reported audited financial results as at and for Q4 2025 after market April 29, 2026. All amounts are in Canadian dollars unless otherwise stated and have been prepared in accordance with IFRS Accounting Standards. Financial Highlights 34% increase in revenues to $4.2 million for Q4 2025 from $3.2 million for Q4 2024 and 17% decrease in fiscal year revenues to $11.
Evogene Ltd. (NASDAQ: EVGN - Get Free Report) shares crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.04 and traded as low as $0.78. Evogene shares last traded at $0.7952, with a volume of 41,345 shares trading hands. Evogene Stock Performance The company has a
REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for 30 consecutive business days.
Today, castor oil is a premium sustainable industrial feedstock for bio-based products REHOVOT, Israel, March 31, 2026 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), a developer of high-yield castor seed varieties and integrated castor farming solutions, and a subsidiary of Evogene Ltd.
Conference will be held at Lisbon, Portugal - March 23–25, 2026 REHOVOT, Israel, March 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced it will be featured as a presenting company at the upcoming BIO-Europe Spring 2026 conference, being held on March 23-25, in Lisbon.
Evogene (NASDAQ: EVGN) executives used the company's fourth-quarter and full-year 2025 results call to outline a strategic transformation that narrowed its technology and market focus, while the finance team detailed the impact of cost reductions, discontinued operations, and several subsidiary-level changes. Strategy shift centers on ChemPass AI and two end markets President and CEO Ofer Haviv
